DOCSLIB.ORG

The Effects of Extended Access to Methamphetamine Self-Administration on Dopaminergic Markers in the Striatum" (2012)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Effects of Extended Access to Methamphetamine Self-Administration on Dopaminergic Markers in the Striatum University of Texas at El Paso DigitalCommons@UTEP Open Access Theses & Dissertations 2012-01-01 The ffecE ts Of Extended Access To Methamphetamine Self-Administration On Dopaminergic Markers In The trS iatum Joe Luevano University of Texas at El Paso, [email protected] Follow this and additional works at: https://digitalcommons.utep.edu/open_etd Part of the Behavioral Neurobiology Commons, Biological Psychology Commons, Molecular Biology Commons, and the Pharmacology Commons Recommended Citation Luevano, Joe, "The Effects Of Extended Access To Methamphetamine Self-Administration On Dopaminergic Markers In The Striatum" (2012). Open Access Theses & Dissertations. 2129. https://digitalcommons.utep.edu/open_etd/2129 This is brought to you for free and open access by DigitalCommons@UTEP. It has been accepted for inclusion in Open Access Theses & Dissertations by an authorized administrator of DigitalCommons@UTEP. For more information, please contact [email protected]. THE EFFECTS OF EXTENDED ACCESS TO METHAMPHETAMINE SELF-ADMINISTRATION ON DOPAMINERGIC MARKERS IN THE STRIATUM JOE LUEVANO Department of Biological Sciences APPROVED: Manuel Miranda Ph.D., Chair Laura O’Dell, Ph.D. Kristin Gosselink, Ph.D. Benjamin C. Flores, Ph.D. Dean of the Graduate School Copyright © By Joe Luevano 2012 THE EFFECTS OF EXTENDED ACCESS TO METHAMPHETAMINE SELF-ADMINISTRATION ON DOPAMINERGIC MARKERS IN THE STRIATUM by Joe Luevano, B.S. THESIS Presented to the Faculty of the Graduate School of The University of Texas at El Paso In Partial Fulfillment of the Requirements for the Degree of MASTER OF SCIENCE Department of Biological Sciences THE UNIVERSITY OF TEXAS AT EL PASO December 2012 ACKNOWELDGEMENTS The research described herein would not have been possible without the support of many people across discipline lines. First and foremost I would like to thank my mentor Dr. Manuel Miranda for his diligent support and patience. I was fortunate enough to have joined his lab as an undergraduate student more than four years ago. I am extremely grateful for the opportunity that Manuel has given me at a time when so many were quick to turn me away. Since then we have worked through the best and worst of times. For his commitment with me, I have much admiration and respect for him as an instructor, mentor and person. I only hope that someday when I become an independent investigator I will have half the amount of dedication and patience for my students as Manuel has for his. He is a major part of my journey and his compassion, understanding and kindness in and outside the lab are things I will never forget. I would next like to thank the support of the Miranda, Khan, O’Dell and Gosselink labs. Without the help and co-operation of the many individuals from these labs the work in this project would have been incomplete. I would like to thank Oscar Torres and Evelyn Escalante for teaching myself and Jonathan Jackson the jugular catheter implant surgeries. I also would like to thank Luis Natividad for teaching myself and Jonathan the operation of the animal behavioral IVSA. A special thanks to Dr. Gosselink and Chris D’Arcy for teaching me how to perfuse and section the animal brain tissue. Thanks to Dr. Arshad Khan for training me on immunohistochemistry design and staining optimization. I would also like to thank the Miranda lab postdocs Dr. Vincent Castecon and Dr. Luciana Gentil for sharing their expert tips and western blotting troubleshooting experiences with me. A sincere thank you to Jonathan Jackson for all his assistance and support, without his help this project would not have been feasible. Thank you to Dr. Christina Sobin for all of the very beneficial writing suggestions and feedback for my Thesis document. I am grateful for everyone’s valuable assistance, without which I would not have been as productive. iv Thank you to the Vulnerability Issues in Drug Abuse (VIDA) program for their financial support on this fascinating research project. Without the hard work and dedication of the many involved in the writing of this exceptional grant this research opportunity would not have been possible. Thank you to VIDA secretary Rosemary Landa-Medlin for all her help with reagent orders, travel arrangements and event organization. Thank you to VIDA director Dr. Edward Castaneda for all his extremely beneficial workshops and support. I wish to acknowledge all of my thesis committee members: Dr. Miranda, Dr. O’Dell and Dr. Gosselink. Your guidance has helped me to complete my work and develop my thesis in a method that would clearly communicate an interesting story. Thank you all for your feedback and cooperation during all the committee meetings we had. I am grateful for the time we spent working on the project and my skills as a young investigator, orator and writer. Thank you to all whom provided me with recommendation letters. Lastly, I would like to thank my parents for being present with me at every step in my academic journey. Without their support I would not have been able to make it as far as I have. Their love, support and encouragement has helped me to gain prospective on the most important aspects on life and thus aided me to finish my graduate studies. v ABSTRACT Methamphetamine (METH) abuse is a persistent problem in the U.S. and abroad. Escalation of METH use among independent users occurs for a variety of physiological and psychological reasons. Methamphetamine dependence may be attributed to the rewarding effect of this drug via the dopaminergic systems of the central nervous system (CNS). The presence of METH in the CNS increases synaptic release of dopamine. This increase in dopaminergic neurotransmission is thought to be directly attributed to the rewarding effects of METH. Following METH use, compensatory changes have been found to occur in the dopaminergic system during various periods of abstinence. It is proposed that these molecular compensatory responses during periods of abstinence following stimulant usage may in part be responsible for facilitating addiction behavior and drug relapse. Previous studies have shown that rats given extended access to methamphetamine self-administration display an escalation of drug intake as compared to animals given limited access to this drug. Many other studies using both self-administration operant conditioning and non-contingent delivery of METH in rodents have found various changes in key dopaminergic proteins following access to high-dose METH under limited durations. However, dopaminergic protein changes which may occur shortly following an extended access (20 days or more) METH paradigm are not well-characterized. The goal of this study was to compare changes in dopaminergic systems in rats allowed extended versus limited access to methamphetamine self-administration following an extended access paradigm. Adult Wistar rats (n=10 extended, n=7 limited, n=8 naïve) were given either extended (6 hr/day) or limited (1 hr/day) access to intravenous self-administration (IVSA) of METH (0.025 mg/infusion) for 28 days. Control rats received surgical implantation of intravenous catheters, but were not given access to METH IVSA. The rats were sacrificed 72 hours after the final self- vi administration session. All groups were compared with respect to striatal dopaminergic protein expression (Tyrosine hydroxylase, TH, dopamine transporter, DAT, and dopamine receptor 2, D2R) using western-blot and immunocytochemistry procedures. The results revealed that rats given extended access to METH displayed an escalation of METH intake during the first hour of each session, and this behavior was not observed in animals given limited access. Seventy-two hours after termination of extended access paradigm the largest changes in striatal dopaminergic markers were observed between drug naïve controls versus rats that self-administered METH for the extended access (6hrs) duration. Western-blot analyses of striatal tissue revealed no significant difference in immunoreactivity for TH between treatment groups and naïve animals. By contrast, a significant increase in total striatal DAT was found in extended access self-administration rats as compared to naive controls. Preliminary immunocytochemistry analysis was consistent with the latter results, suggesting an increase in the levels of DAT throughout the corpus striatum. On the other hand, no significant changes were found between METH IVSA and naïve controls for D2R striatal immunoreactivity. Taken together, our results revealed that rats allotted 6 hours access to METH IVSA showed an escalation of intake compared to rats allotted 1 hour of access. In addition, it was found that expression of dopaminergic markers in the striatum were altered after extended methamphetamine self-administration access. These findings cast new insight into the molecular mechanism of long-term METH use and subsequent escalation, which may evoke cravings for sustained use and relapse during initial periods of withdrawal. vii TABLE OF CONTENTS ACKNOWLEDGEMENTS…………………………………………………………………………….....iv ABSTRACT……………………………………………………………………………………………….vi TABLE OF CONTENTS………………………………………………………………………………..viii LIST OF TABLES………………………………………………………………………………………....x LIST OF FIGURES……………………………………………………………………………………….xi Chapter 1 CHAPTER 1: INTRODUCTION………………………………………………………………..1 1.1 Stimulants of Abuse………………………………………………………………………..1 1.2 Molecular Characterization…………………………………………………………………3 1.3 The Reward Pathway……………………………………………………………………….5 1.4 Addiction Behavior and Neural Plasticity………………………………………………..8
Load more

Recommended publications
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
    (19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes.
    [Show full text]
  • ALC Neuroprotection in Mitochondrial Dysfunction V2 Mar2013x
    LÍDIA ALEXANDRA DOS SANTOS CUNHA ACETYL -L-CARNITINE NEUROPROTECTION IN MITOCHONDRIAL DYSFUNCTION Tese de Candidatura ao Grau de Doutor em Patologia e Genética Molecular, submetida ao Instituto de Ciências Biomédicas Abel Salazar Universidade do Porto Orientadora: Doutora Maria Teresa Burnay Summavielle Categoria: Investigador Auxiliar Afiliação: Instituto de Biologia Molecular e Celular DIRECTIVAS LEGAIS Nesta Tese foram apresentados os resultados contidos nos artigos publicados ou em vias de publicação seguidamente mencionados: Cunha L , Horvath I, Ferreira S, Lemos J, Costa P, Vieira D, Veres DS, Szigeti K, Summavielle T, Máthé D, Metello LF Preclinical imaging: an essential ally in biosciences and drug development (Submitted for publication) Cunha L , Bravo J, Fernandes S, Magalhães A, Costa P, Metello LF, Horvath I, Borges F, Szigeti K, Máthé D, Summavielle T Acetyl-L-Carnitine preconditioning in methamphetamine exposure leads to excessive glucose uptake impairing reference memory and deregulated mitochondrial membrane function (Submitted for publication) Summavielle T, Cunha L , Damiani D , Bravo J, Binienda Z, Koverech A , Virmani A (2011) Neuroprotective action of acetyl-L-carnitine on methamphetamine-induced dopamine release . American Journal of Neuroprotection and Neuroregeneration 3:1-7. Comunicações orais apresentadas em congressos internacionais: Cunha L , Bravo J, Gonçalves R, Rodrigues C, Rodrigues A, Metello LF, Summavielle T The role of mitochondria in acetyl-L-carnitine neuroprotective action European Association of Nuclear Medicine Annual Congress. October 2012. Birmingham, UK. Eur J Nucl Med Mol Imaging (2011) 38 (Suppl 2):S227 iii Apresentações sob a forma de poster em congressos internacionais: Cunha L , Bravo J, Costa P, Fernandes S, Oliveira M, Castro R, Metello LF, Summavielle T Acetyl-L-carnitine improves cell bioenergetics European Association of Nuclear Medicine Annual Congress.
    [Show full text]
  • Phencyclidine: an Update
    Phencyclidine: An Update U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse and Mental Health Administration Phencyclidine: An Update Editor: Doris H. Clouet, Ph.D. Division of Preclinical Research National Institute on Drug Abuse and New York State Division of Substance Abuse Services NIDA Research Monograph 64 1986 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administratlon National Institute on Drug Abuse 5600 Fishers Lane Rockville, Maryland 20657 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 NIDA Research Monographs are prepared by the research divisions of the National lnstitute on Drug Abuse and published by its Office of Science The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. SIDNEY COHEN, M.D. Temple University School of Medicine Los Angeles, California Philadelphia, Pennsylvania SYDNEY ARCHER, Ph.D. MARY L. JACOBSON Rensselaer Polytechnic lnstitute National Federation of Parents for Troy, New York Drug Free Youth RICHARD E. BELLEVILLE, Ph.D. Omaha, Nebraska NB Associates, Health Sciences Rockville, Maryland REESE T. JONES, M.D. KARST J. BESTEMAN Langley Porter Neuropsychiatric lnstitute Alcohol and Drug Problems Association San Francisco, California of North America Washington, D.C. DENISE KANDEL, Ph.D GILBERT J. BOTV N, Ph.D. College of Physicians and Surgeons of Cornell University Medical College Columbia University New York, New York New York, New York JOSEPH V.
    [Show full text]
  • Terminoloogia Raamat.Pdf
    A I G O O L O N I M R E T A I S T A A M R A F FARMAATSIATERMINOLOOGIA Euroopa farmakopöa ravimvormid, manustamisviisid, pakendid ja droogid ATC süsteemid FARMAATSIATERMINOLOOGIA Euroopa farmakopöa ravimvormid, manustamisviisid, pakendid ja droogid ATC süsteemid Tartu 2010 Koostajad: Toivo Hinrikus, Mailis Jaamaste, Eveli Kikas, Peet-Henn Kingisepp, Ott Laius, Ain Raal, Sander Sepp, Ave-Ly Toomvap, Peep Veski, Daisy Volmer Farmaatsiaterminoloogia ekspertkomisjoni liikmed aastast 1999 (Tartu Ülikool): Toivo Hinrikus, Peet-Henn Kingisepp, Ain Raal, Peep Veski, Daisy Volmer Farmaatsiaterminoloogia ekspertkomisjoni liikmed aastatel 1999–2009 (Ravimiamet): Birgit Aasmäe, Malle Jaagola, Mailis Jaamaste, Eveli Kikas, Silja Kokk, Signe Leito, Margit Plakso, Lembit Rägo, Helga Suija, Ave-Ly Toomvap, Merje Veeberg Keeletoimetaja: Rutt Läänemets Kaanefoto: Ain Raal Kirjastanud: Ravimiamet Nooruse 1, 50411 Tartu Telefon: +372 737 4140 Faks: +372 737 4142 E-post: [email protected] Trükise väljaandmist toetasid Eesti Terminoloogia Ühing ja Haridus- ja Teadusministeerium projekti „Terminikomisjonide toetuskonkurss 2009“ raames. Väljaande refereerimisel või tsiteerimisel palume viidata allikale. ISBN 978-9949-18-919-9 Saateks Räägime ravimitest eesti keeles Ravimimaailmas toimub üleilmastumine tohutu hooga. Sageli mõeldakse ravim välja ühes, selle omadusi ja toimet hinnatakse teises ning seda toodetakse kolmandas maailma nurgas. Sama ravimit võivad kasutada arstid, apteekrid ja patsiendid üle kogu maailma. Kui ravimi kõrvaltoime registreeritakse näiteks Portugalis, peame meiegi Eestis sellest oma järel- dused tegema ja teadma, mis on sellest oluline meie patsientide jaoks. Selleks, et ravimitega tegelejad erinevates riikides üksteist mõistaksid, peavad nad kasutama ühtset terminoloogiat. Nüüdisajal on üldkasutatavaks suhtlemisvahendiks teatavasti inglise keel. Just inglise keeles trükitud Euroopa farmakopöa on aluseks ravimitega seonduvate terminite kasuta- misele kogu Euroopas.
    [Show full text]
  • G-33-667 Cost Share
    11:40:18 OCA PAD INITIATION - PROJECT HEADER INFORMATION 12/13/89 Active Project #: G-33-667 Cost share #: Rev #: 0 Center # : 10/24-6-R6834-1A0 Center shr #: OCA file #: Work type : RES Contract#: 1 RO1 DA06305-01 Mod #: Document : GRANT Prime #: Contract entity: GTRC Subprojects ? : N Main project #: Project unit: CHEM Unit code: 02.010.136 Project director(s): ZALKOW L H CHEM (404)894-4045 Sponsor/division names: DHHS/PHS/ADAMHA / ALCOHOL, DRUG ABUSE & MENTAL Sponsor/division codes: 108 / 004 Award period: 890930 to 900831 (performance) 901130 (reports) Sponsor amount New this change Total to date Contract value 187,296.00 187,296.00 Funded 187,296.00 187,296.00 Cost sharing amount 0.00 Does subcontracting plan apply ?: N Title: IRREVERSIBLE ANTAGONISTS OF COCAINE AND OTHER STIMULANTS PROJECT ADMINISTRATION DATA OCA contact: Kathleen R. Ehlinger 894-4820 Sponsor technical contact Sponsor issuing office KIM PHAM, PH.D. CATHERINE MILLS (301)443-5280 (301)443-6024 NATIONAL INSTITUTE ON DRUG ABUSE NATIONAL INSTITUTE ON DRUG ABUSE 5600 FISHERS LANE 5600 FISHERS LANE, ROOM 10-25 ROCKVILLE, MD. 20857 ROCKVILLE, MD. 20857 Security class (U,C,S,TS) : U ONR resident rep. is ACO (Y/N): N Defense priority rating : N/A N1H supplemental sheet Equipment title vests with: Sponsor GIT X Administrative comments - INITIATION OF PROJECT. YEAR 1 OF PROPOSED 3 YEAR PROJECT. GEORGIA INSTITUTE OF TECHNOLOGY OFFICE OF CONTRACT ADMINISTRATION NOTICE OF PROJECT CLOSEOUT Cloaeout Notice Date 03/19/91 Project No. G-33-667 Center No. 10/24-6-R6834-1A0_ Project Director ZALKOW L H School/Lab CHEMISTRY Sponsor DHHS/PHS/ADAMHA/ALCOHOL, DRUG ABUSE & MENTAL Contract/Grant No.
    [Show full text]
  • Neurotoxicity and Neuropathology Associated with Cocaine Abuse
    Neurotoxicity and Neuropathology Associated with Cocaine Abuse Editor: Maria Dorota Majewska, Ph.D. NIDA Research Monograph 163 1996 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse Medications Development Division 5600 Fishers Lane Rockville, MD 20857 i ACKNOWLEDGMENT This monograph is based on the papers from a technical review on "Neurotoxicity and Neuropathology Associated with Cocaine Abuse" heldon July 7-8, 1994. The review meeting was sponsored by the National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder's permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company. Trade, proprietary, or company names appearing in this publication are used only because they are considered essential in the context of the studies reported herein. National Institute on Drug Abuse NIH Publication No.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Farmaatsia- Terminoloogia Teine, Täiendatud Trükk
    Farmaatsia- terminoloogia Teine, täiendatud trükk Graanulid Suspensioon Lahus Emulsioon Pillid Pulber Salv Kreem Aerosool Plaaster Sprei Pastill Tampoon Oblaat Emulsioon Kontsentraat Silmageel Tablett Haavapulk Ninatilgad Kapsel Lakukivi Inhalaator Farmaatsia- terminoloogia Teine, täiendatud trükk Tartu 2019 Koostajad: Toivo Hinrikus, Karin Kogermann, Ott Laius, Signe Leito, Ain Raal, Andres Soosaar, Triin Teppor, Daisy Volmer Keeletoimetaja: Tiina Kuusk Kirjastanud: Ravimiamet Nooruse 1, 50411 Tartu Telefon: +372 737 4140 Faks: +372 737 4142 E-post: [email protected] Esimene trükk 2010 Teine, täiendatud trükk 2019 Raamat on leitav Ravimiameti veebilehelt: www.ravimiamet.ee/farmaatsiaterminoloogia Väljaande refereerimisel või tsiteerimisel palume viidata allikale. ISBN 978-9949-9697-3-9 Sisukord Farmaatsiaterminoloogia Eestis..........................................................................................5 Üldised farmaatsiaalased terminid ...................................................................................10 Euroopa farmakopöa ......................................................................................................... 21 Euroopa farmakopöa sõnastik ..........................................................................................24 Standardterminid ..............................................................................................................29 Ravimvormid .....................................................................................................................29
    [Show full text]
  • Cocaine Increases Dopamine Release by Mobilization of a Synapsin-Dependent Reserve Pool
    3206 • The Journal of Neuroscience, March 22, 2006 • 26(12):3206–3209 Brief Communications Cocaine Increases Dopamine Release by Mobilization of a Synapsin-Dependent Reserve Pool B. Jill Venton,1 Andrew T. Seipel,1 Paul E. M. Phillips,2 William C. Wetsel,3 Daniel Gitler,4 Paul Greengard,5 George J. Augustine,4 and R. Mark Wightman1 1Department of Chemistry and Neuroscience Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, 2Department of Psychiatry and Behavioral Sciences and Department of Pharmacology, University of Washington, Seattle, Washington 98195, 3Departments of Psychiatry and Behavioral Sciences, Medicine (Endocrinology), and Cell Biology, and Mouse Behavioral and Neuroendocrine Analysis Core Facility, and 4Department of Neurobiology, Duke University Medical Center, Durham, North Carolina 27710, and 5Laboratory of Molecular and Cellular Neuroscience, Rockefeller University, New York, New York 10021 Cocaine primarily exerts its behavioral effects by enhancing dopaminergic neurotransmission, amplifying dopamine-encoded sensori- motorintegration.Thepresumedmechanismforthiseffectisinhibitionofthedopaminetransporter,whichblocksdopamineuptakeand prolongs the duration of dopamine in the extracellular space. However, there is growing evidence that cocaine can also augment dopa- mine release. Here, we directly monitored the actions of cocaine on dopamine release by using electrochemical detection to measure extracellular dopamine in the striatum of anesthetized mice. Cocaine enhanced the levels of striatal dopamine produced by electrical stimulation of dopaminergic neurons. Even after pretreatment with ␣-methyl-p-tyrosine, which depletes the readily releasable pool of dopamine, cocaine was still capable of elevating dopamine levels. This suggests that cocaine enhances dopamine release by mobilizing a reserve pool of dopamine-containing synaptic vesicles. To test this hypothesis, we examined electrically evoked dopamine release in synapsin I/II/III triple knock-out mice, which have impaired synaptic vesicle reserve pools.
    [Show full text]
  • Methamphetamine-Induced Degeneration of Dopaminergic Neurons Involves Autophagy and Upregulation of Dopamine Synthesis
    The Journal of Neuroscience, October 15, 2002, 22(20):8951–8960 Methamphetamine-Induced Degeneration of Dopaminergic Neurons Involves Autophagy and Upregulation of Dopamine Synthesis Kristin E. Larsen,1 Edward A. Fon,2 Teresa G. Hastings,3 Robert H. Edwards,4 and David Sulzer1 1Departments of Neurology and Psychiatry, Columbia University, and Department of Neuroscience, New York Psychiatric Institute, New York, New York 10032, 2Centre for Neuronal Survival, Montreal Neurological Institute, McGill University, Montreal, Quebec H3A 2B4, Canada, 3Departments of Neuroscience and Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, and 4Departments of Neurology and Physiology, University of California, San Francisco, California 94143 Methamphetamine (METH) selectively injures the neurites of pression. METH administration also promoted the synthesis of dopamine (DA) neurons, generally without inducing cell death. It DA via upregulation of tyrosine hydroxylase activity, resulting in has been proposed that METH-induced redistribution of DA an elevation of cytosolic DA even in the absence of vesicular from the vesicular storage pool to the cytoplasm, where DA can sequestration. Electron microscopy and fluorescent labeling oxidize to produce quinones and additional reactive oxygen confirmed that METH promoted the formation of autophagic species, may account for this selective neurotoxicity. To test granules, particularly in neuronal varicosities and, ultimately, this hypothesis, we used mice heterozygous (ϩ/Ϫ) or homozy- within cell bodies of dopaminergic neurons. Therefore, we pro- gous (Ϫ/Ϫ) for the brain vesicular monoamine uptake trans- pose that METH neurotoxicity results from the induction of a porter VMAT2, which mediates the accumulation of cytosolic specific cellular pathway that is activated when DA cannot be DA into synaptic vesicles.
    [Show full text]
  • Enduring Changes in Brain and Behavior Produced by Chronic Amphetamine Administration: a Review and Evaluation of Animal Models of Amphetamine Psychosis
    Brain Research Reviews, 11 (1986) 157-198 157 Elsevier BRR 90048 Enduring Changes in Brain and Behavior Produced by Chronic Amphetamine Administration: A Review and Evaluation of Animal Models of Amphetamine Psychosis TERRY E. ROBINSON and JILL B. BECKER Department of Psychology and Neuroscience Laboratory Building, The University of Michigan, Ann Arbor, M148104-1687 (U.S.A.) (Accepted December 31st, 1985) Key words: amphetamine -- sensitization -- reverse tolerance -- dopamine -- catecholamine -- schizophrenia -- amphetamine psychosis -- animal model -- striatum-- stress-- sex difference -- conditioning-- neurotoxicity -- stereotypy -- autoreceptor CONTENTS 1. Introduction ............................................................................................................................................ 158 2. The effects of continuous amphetamine administration on brain and behavior (amphetamine neurotoxicity) ..................... 159 3. The behavioral consequences of repeated intermittent amphetamine administration (behavioral sensitization) ................. 160 3 1. The major characteristics of behavioral sensitization .................................................................................... 161 3.1.1. Behavior .................................................................................................................................. 161 3.1.2. Injection paradigm ..................................................................................................................... 163 3.1.3. Sex differences
    [Show full text]